1. Progression-free and overall survival was comparable in both the intervention and control groups. 2. Serious adverse events were more common among patients taking a combination of atezolizumab-cabozantinib than cabozantinib-only. Evidence Rating Level: 1 (Excellent) Study Rundown: Immune checkpoint inhibitors are first-line therapy for patients with metastatic renal cell carcinoma (MRCC); however, optimal management for
Related Keywords
, Rating Level , Advanced Renal Cell , Between Jul , Atezolizumab , Cabozantinib , Immune Checkpoint Inhibitors , Kidney , Kidney Cancer , Metastatic Renal Cell Carcinoma , Oncology , Renal Cell Carcinoma , Vegf Inhibitors , Chronic Disease , Nephrology ,
comparemela.com © 2020. All Rights Reserved.